A month has gone by since the last earnings report for Conmed (CNMD) . Shares have added about 0.1% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late.CONMED Q3 Earnings and Revenues Beat ...

A month has gone by since the last earnings report for Henry Schein (HSIC) . Shares have added about 1.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Henry Schein due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Henry Schein, Inc. before we dive into how investors and analysts have reacted as of late.HSIC Q3 Earnings and Rev ...

Core Insights - Dentsply International reported quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share, and down from $0.50 per share a year ago, representing an earnings surprise of -17.78% [1] - The company posted revenues of $904 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.27%, but down from $951 million year-over-year [2] - Dentsply shares have declined approximately 33.5% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $931.32 million, and for the current fiscal year, it is $1.87 on revenues of $3.65 billion [7] Estimate Revisions - The trend of estimate revisions for Dentsply was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Overview - Pro-Dex, Inc. (PDEX) shares increased by 8.2% to $53.5 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has gained 10.1% over the past four weeks, indicating a positive trend [1] Institutional Interest - The recent surge in PDEX shares is attributed to growing institutional interest, with significant investors like Navellier & Associates and Northern Trust either initiating or expanding their positions [2] - This accumulation reflects increasing confidence in the company's fundamentals, supporting the stock's upward momentum that began in August 2024 [2] Earnings Expectations - Pro-Dex is projected to report quarterly earnings of $0.47 per share, representing a year-over-year increase of 2.2% [3] - Expected revenues for the upcoming report are $17.9 million, which is a 19.2% increase compared to the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Pro-Dex has remained unchanged over the last 30 days, suggesting that the stock's price movement may not sustain without trends in earnings estimate revisions [4] - Monitoring PDEX is advised to determine if the recent price increase can lead to further strength in the future [4] Industry Context - Pro-Dex operates within the Zacks Medical - Dental Supplies industry, where McKesson (MCK) is another key player [5] - McKesson's consensus EPS estimate has changed by 1.1% over the past month to $8.23, reflecting a year-over-year change of 4.4% [6]

Core Viewpoint - Labcorp's shares have increased by approximately 2.5% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings and Estimates - Recent estimates for Labcorp have trended downward over the past month [2] - The magnitude of estimate revisions for Labcorp has been net zero, indicating stability in expectations [4] Group 2: VGM Scores and Rankings - Labcorp has a subpar Growth Score of D and a similar score for momentum, but a B grade for value, placing it in the top 40% for this investment strategy [3] - The overall VGM Score for Labcorp is C, which is relevant for investors not focused on a single strategy [3] - Labcorp holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return in the coming months [4] Group 3: Industry Performance - Labcorp is part of the Zacks Medical - Dental Supplies industry, where West Pharmaceutical Services has seen a slight gain of 0.1% over the past month [5] - West Pharmaceutical reported revenues of $698 million for the last quarter, reflecting a year-over-year increase of 0.4% [5] - The expected earnings for West Pharmaceutical for the current quarter is $1.51 per share, indicating a year-over-year decline of 0.7% [6]